Hypertension in continuous ambulatory peritoneal dialysis patients: what do we know and what can we do about it?

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Continuous ambulatory peritoneal dialysis (CAPD) offers hemodynamic stability but is associated with high rates of hypertension (50%-60%).
• Hypertension in CAPD patients necessitates antihypertensive treatment, often involving ACE inhibitors and beta-blockers as first-line therapy.
• Despite treatment, many CAPD patients struggle to maintain optimal blood pressure (BP) ranges, contributing to cardiovascular complications.

Purpose of the Study:

• To highlight the challenges in managing hypertension in CAPD patients.
• To emphasize the need for vigilant BP monitoring and management in CAPD.
• To advocate for a comprehensive strategy addressing all cardiovascular risk factors in dialysis patients.

Main Methods:

• Review of existing literature on hypertension management in CAPD patients.
• Analysis of the role of first-line antihypertensives (ACE inhibitors, beta-blockers) and add-on therapies (calcium antagonists).
• Discussion of the impact of suboptimal BP control on cardiovascular outcomes.

Main Results:

• A significant proportion of CAPD patients (50%-60%) have hypertension requiring treatment.
• First-line antihypertensives may not be sufficient, necessitating additional agents like calcium antagonists.
• Failure to maintain optimal BP is linked to increased cardiovascular morbidity and mortality.

Conclusions:

• Effective hypertension management in CAPD patients requires ongoing vigilance from both patients and physicians.
• A multifaceted approach targeting all cardiovascular risk factors is essential for reducing mortality in dialysis patients.
• Optimizing BP control is a critical component of comprehensive care for CAPD patients.